Effects of citalopram on hostility and CHD risk

“敌意”指的是一系列特征，这些特征似乎与中枢血清素功能减弱或失调有关，也与许多与冠心病（CHD）风险相关的生活方式和生物学变量有关。例如，敌意已被证明与吸烟和饮酒增加、不健康的饮食模式、脂质浓度改变、自主神经平衡改变、压力相关心血管反应性增加和血小板活化增加有关。越来越多的证据表明，敌意特征与冠心病事件和死亡率增加有关：这些不健康的行为和生物学过程可能部分解释了观察到的敌意和冠心病之间的关联。选择性5 -羟色胺再摄取抑制剂（SSRIs）可以提高5 -羟色胺神经传递的效率，已被证明可以减少精神病样本中的敌意特征，一些证据表明它们在正常志愿者中可能有类似的效果。目前还没有已发表的数据研究SSRI干预措施对先前与冠心病风险相关的敌意措施的影响。此外，这些干预措施对与冠心病相关的多种行为和生物学变量的潜在影响尚未得到系统的探讨。本项目是一项安慰剂对照试验，旨在检查短期（3个月）SSRI治疗对正常志愿者敌意和攻击性变化的影响，选择高敌意志愿者。我们还将研究这种干预对与冠心病风险相关的生活方式相关行为改变的影响，包括吸烟、饮酒和不健康的饮食模式；以及疾病风险的生物标志物的变化，包括脂质、葡萄糖和胰岛素、自主神经平衡、与压力相关的心血管反应性和血小板活化。这项研究的重要性体现在三个方面。首先，它将帮助我们了解一些与冠心病相关的心理特征的中枢神经系统相关。其次，它将帮助我们探索冠心病风险的一些共同的行为起源和生物学指标。其次，它将帮助我们探索冠心病风险的行为和生物学指标的一些共同起源。第三，这项研究可能最终会对冠心病危险因素干预的新方法的发展产生影响。

"Hostility" refers to a set of characteristics that appear to be associated with diminished or dysregulated central serotonergic function, and that are linked, as well, with a number of lifestyle and biological variables associated with coronary heart disease (CHD) risk. For example, hostility has been shown to be associated with increased smoking and alcohol consumption, unhealthy dietary patterns, altered lipid concentrations, alterations in autonomic balance, increase stress-related cardiovascular responsiveness, and increased platelet activation. Accumulating evidence suggests that hostile characteristics are associated with increased risk for CHD events and mortality: These unhealthy behavioral and biological processes may account, in part, for the observed associations between hostility and CHD. Selective serotonin reuptake inhibitors (SSRIs), which increase the efficiency of serotonergic neurotransmission, have been shown to reduce hostile traits in psychiatric samples, and some evidence suggests that they may have similar effects in normal volunteers. There are no published data examining the effects of SSRI interventions on measures on hostility previously linked with CHD risk. Moreover, the potential impact of such interventions on multiple behavioral and biological variables of relevance to CHD has not been systematically explored. This project is a placebo-controlled trial designed to examine the effects of short term (3 month) SSRI treatment on changes in hostility and aggression in normal volunteers, selected for high hostility. We will also examine the effects of this intervention on changes in lifestyle- related behaviors associated with CHD risk, including smoking, alcohol consumption, and unhealthy dietary patterns; and on changes in biological markers of disease risk, including lipids, glucose and insulin, autonomic balance, stress-related cardiovascular responsiveness, and platelet activation. This research is important in 3 ways. First, it will help us to understand some of the CNS correlates of psychological traits relevant to CHD. Second, it will help us to explore some of the common origins of behavior and biological indices of CHD risk.. Second, it will help us explore some of the common origins of the behavioral and biological indices of CHD risk. And third, this research may eventually have implications for the development of new approaches to CHD risk factor intervention.